{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang Z"],"funding":["Beijing Municipal Natural Science Foundation","Beijing Xisike Clinical Oncology Research Foundation","Clinical Research Fund For Distinguished Young Scholars of Peking University Cancer Hospital","National Natural Science Foundation of China"],"pagination":["182"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11226604"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["73(9)"],"pubmed_abstract":["<h4>Background</h4>The long-term survival benefit of immune checkpoint inhibitors (ICIs) in neoadjuvant and adjuvant settings is unclear for colorectal cancers (CRC) and gastric cancers (GC) with deficiency of mismatch repair (dMMR) or microsatellite instability-high (MSI-H).<h4>Methods</h4>This retrospective study enrolled patients with dMMR/MSI-H CRC and GC who received at least one dose of neoadjuvant ICIs (neoadjuvant cohort, NAC) or adjuvant ICIs (adjuvant cohort, AC) at 17 centers in China. Patients with stage IV disease were also eligible if all tumor lesions were radically resectable.<h4>Results</h4>In NAC (n = 124), objective response rates were 75.7% and 55.4%, respectively, in CRC and GC, and pathological complete response rates were 73.4% and 47.7%, respectively. The 3-year dis"],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers."],"pmcid":["PMC11226604"],"funding_grant_id":["Y-HH202101-0068, Y-tongshu2021/ms-0040","General Program, no. 82272764","Y-XD202001/zb-0008","QNJJ2022026","No. 7232018"],"pubmed_authors":["Shen L","Deng T","Zou J","Zhang J","Liu N","Zhang H","Qu H","Liu S","Gao H","Cao B","Peng Z","Wang L","Cheng S","Liu Z","Yao Y","Bao L","Wang Q","Chen Z","Wang X","Wang Z","Tang Y","Li J","Xu C","Jin Y","Sun Y","Yin F","Lu H","Zhang Y","Fang W","Han G","Xu T","Yan D","Ji Z"],"additional_accession":[]},"is_claimable":false,"name":"Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers.","description":"<h4>Background</h4>The long-term survival benefit of immune checkpoint inhibitors (ICIs) in neoadjuvant and adjuvant settings is unclear for colorectal cancers (CRC) and gastric cancers (GC) with deficiency of mismatch repair (dMMR) or microsatellite instability-high (MSI-H).<h4>Methods</h4>This retrospective study enrolled patients with dMMR/MSI-H CRC and GC who received at least one dose of neoadjuvant ICIs (neoadjuvant cohort, NAC) or adjuvant ICIs (adjuvant cohort, AC) at 17 centers in China. Patients with stage IV disease were also eligible if all tumor lesions were radically resectable.<h4>Results</h4>In NAC (n = 124), objective response rates were 75.7% and 55.4%, respectively, in CRC and GC, and pathological complete response rates were 73.4% and 47.7%, respectively. The 3-year dis","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-07-15T08:20:42.491Z","creation":"2025-04-04T12:20:28.391Z"},"accession":"S-EPMC11226604","cross_references":{"pubmed":["38967817"],"doi":["10.1007/s00262-024-03764-9"]}}